THERAPEUTIC POTENTIAL OF METFORMIN: INFLUENCE ON CARBOHYDRATE METABOLISM AND VASOACTIVE NITRIC OXIDE POOL IN PATIENTS WITH COMORBID PATHOLOGY

Authors

  • Kovalyova O. M. Kharkiv National Medical University
  • Demydenko G. V. Kharkiv National Medical University
  • Ambrosova T. M. Kharkiv National Medical University

DOI:

https://doi.org/10.21856/j-PEP.2012.4.09

Keywords:

essential hypertension, type 2 diabetes mellitus, comorbid state, nitric oxide, metformin

Abstract

It studied the metformin action on vasoactive nitric oxide pool in patients with essential hypertension with accompanied type 2 diabetes mellitus. Treatment with metformin during 3 months caused positive influence on vasoactive nitric oxide pool in patients with essential hypertension with accompanied type 2 diabetes mellitus. Pharmacologic effects of metformin connect with increasing of endothelial nitric oxide synthase, decreasing if inducible nitric oxide synthase, glicemic control, diminishing of insulin, glicated hemoglobin and insulin resistance indexes. Metformin as a first choice medicine for the patients with essential hypertension and type 2 diabetes mellitus doesn’t cause and complication that leads to the cancelling of the treatment.

References

New ADA/EASD Concensus recommends metformin at diagnosis of type 2 diabetes [Text] / Diabetes Care. — 2006. — Vol. 29 (8). — P. 1963–1972.

Wiernsperger, N. F. Microcirculation in insulin resistance and diabetes: more than just a complication [Text] / N. F. Wiernsperger, E. Bouskela // Diabetes. Metabol. — 2003. — Vol. 29. — P. 6S77–6S87.

Mancia, G. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document [Text] / G. Mancia, S. Laurent, E. Agabiti — Rosei [et al.] // J. Hypertension. — 2009. –Vol. 27. — P. 2121–2158.

Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans [Text] / A. Katz, S. Nambi, K. Mather [et al.] // J. Clin. Endocrinol. Metabol. — 2000. — Vol. 85. — P. 2410–20.

Caro, F. Insulin resistance in obese and nonobese man [Text] / Clin. Endocrinol. Metabol. — 1991. — Vol. 73. — P. 691–695.

Ковальова, О. М. Дiагностика ендотелiальної функцiї — оцiнка вазоактивного пулу оксиду азота. Методичнi рекомендацiї [Текст] // О. М. Ковальова, Г. В. Демиденко, Т. В. Горбач. — К., 2007. — 19 с.

Kirpichnikov, D. Metformin. An Update [Text] / D. Kirpichnikov, S. I. McFarlane, J. R. Sowers //Ann. Intern. Med. — 2002. — Vol. 137. — P. 25–33.

Selective decreased in visceral fat is associated with weight loss during metformin treatment in African Americans with type 2 diabetes [Text] / R. Kurukulasuriya, M. Banerij, R. Chaiken, H. Lebovitz // Diabetes. — 1999. — Vol. 48. — P. A315.

Metformin restores the penile expression of nitric oxide synthase in high fat–fed obese rats [Text] / Y.W. Kim, S. Y. Park, J. Y. Kim, J. Y. Huh // J. Androl. — 2007. — Vol. 26 (3). — P. 34–38.

De Aquiar, L. G. Metformin improves endothelial vascular reactivity in first–degree relatives of type diabetic patient with metabolic syndrome and normal glucose tolerance [Text] / L. G. De Aquiar, L. R. Bahia, N. Villela // Diabetes Care. — 2006. —

Vol. 29 (5). — P. 1083–1089.

Davis, B. J. Activation of the AMP–activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase [Text] / B. J. Davis, Z. Xie, B. Viollet,

M. H. Zou // Diabetes. — 2006. — Vol. 55 (2). – P. 496–450.

Mamputu, J. C. Antiatherogenic properties of metformin: the experimental evidence [Text] / J. C. Mamputu, N. F. Wiernsperger, G. A. Renier // Diabetes Metabol. — 2003. — Vol. 29 (6). — P. 71–76.

Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes [Text] / T. Matsumoto, E. Noguchi, K. Ishida [et al.] //Am. J. Physiol. Heart. Circ. Physiol. — 2008. — Vol. 295 (3). — P. 1165–1176.

Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double–blind, placebo–controlled study [Text] / S. Jadhav, W. Ferrell, I. A. Greer [et al.] // J. Am. Coll. Cardiol. — 2006. — Vol. 48 (5). — P. 956–963.

Fay, W. P. Vascular functions of the plasminogen activation system [Text] / W. P. Fay, N. Garg, M. Sunkar // Arterioscler. Thromb. Vasc. Biol. — 2007. — Vol. 27 (6). — P. 1231–1237.

Rossignol, P. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques [Text] / P. Rossignol, A. Luttun, J. L. Martin-Ventura [et al.] // J. Thromb. Haemost. — 2006. — Vol. 4 (3). — P. 664–670.

Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis [Text] / J. F. Arenillas, J. Álvarez-Sabín, C. A. Molina [et al.] // Stroke. — 2008. — Vol. 39. — P. 1456–1463.

Fryer, L. G. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways [Text] / L. G. Fryer, A. Parbu-Patel, D. Carling // J. Biol. Chem. — 2002. — Vol. 277. — P. 25226–25232.

The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism [Text] / S. A. Hawley, A. E. Gadalla, G. S. Olsen, D. G. Hardie // Diabetes. — 2002. — Vol. 51. —

P. 2420–2425.

Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase [Text] / W. J. Lee, I. K. Lee, H. S. Kim [et al.] // Arterioscler. Thromb. Vasc. Biol. — 2005. — Vol. 25. — P. 2488–2494.

Downloads

Published

2012-12-25

How to Cite

Kovalyova, O. M., Demydenko, G. V., & Ambrosova, T. M. (2012). THERAPEUTIC POTENTIAL OF METFORMIN: INFLUENCE ON CARBOHYDRATE METABOLISM AND VASOACTIVE NITRIC OXIDE POOL IN PATIENTS WITH COMORBID PATHOLOGY. Problems of Endocrine Pathology, 42(4), 57-64. https://doi.org/10.21856/j-PEP.2012.4.09

Issue

Section

CLINICAL ENDOCRINOLOGY